NewLimit
Funding History
| Series B Extension · 10/2025 | $1.6B |
|---|---|
| Series C · 06/2026 | $3.1B |
About
NewLimit is a South San Francisco-based biotechnology company founded in December 2021 by Coinbase co-founder and CEO Brian Armstrong, former GV partner and bioengineer Blake Byers, and stem cell biologist Jacob Kimmel, who serves as NewLimit's President and CEO. The company develops medicines based on partial epigenetic reprogramming, a technique intended to restore youthful gene-expression patterns in aging cells without erasing a cell's identity, with an initial focus on reversing cellular aging in the liver.
- CEO
- Jacob Kimmel
- Headquarters
- South San Francisco, CA
- Founded
- 2021
- Website
- https://www.newlimit.com
Overview
NewLimit is a South San Francisco-based biotechnology company founded in December 2021 by Coinbase co-founder and CEO Brian Armstrong, former GV partner and bioengineer Blake Byers, and stem cell biologist Jacob Kimmel, who serves as NewLimit's President and CEO. The company develops medicines based on partial epigenetic reprogramming, a technique intended to restore youthful gene-expression patterns in aging cells without erasing a cell's identity, with an initial focus on reversing cellular aging in the liver.
NewLimit has raised more than $600 million in disclosed venture financing since its 2021 founding, most recently a $435 million Series C round led by Founders Fund at a roughly $3.1 billion post-money valuation. The company says the raise will fund its first human clinical trial of an aging-reprogramming liver medicine, positioning NewLimit among the best-capitalized private companies pursuing cellular-reprogramming therapeutics for aging.
Private securities are speculative, illiquid, and involve risk of complete loss of principal. You should be prepared to hold private securities for an extended period; there is no assurance of a secondary market, an IPO, or other liquidity event. You are fully responsible for conducting your own due diligence. Pricing is indicative — nothing here is an offer of securities.